The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin)
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
Takara Bio Europe will distribute MN’s Bioanalysis portfolio in Austria, Belgium, Denmark, France, Germany, Ireland, Luxembourg, Sweden, Switzerland, and the United Kingdom
The company expects meaningful revenue contribution from this long-term agreement
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
Subscribe To Our Newsletter & Stay Updated
